About Sera Prognostics, Inc.
https://seraprognostics.comSera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies.
CEO
Evguenia Lindgardt
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 13
Ratings Snapshot
Rating : C
Price Target
Institutional Ownership
BAKER BROS. ADVISORS LP
Shares:5.5M
Value:$19.46M
WHETSTONE CAPITAL ADVISORS, LLC
Shares:3.63M
Value:$12.86M
INTERWEST VENTURE MANAGEMENT CO
Shares:2.42M
Value:$8.55M
Summary
Showing Top 3 of 70
About Sera Prognostics, Inc.
https://seraprognostics.comSera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $16K ▼ | $8.96M ▼ | $-7.81M ▲ | -48.84K% ▼ | $-0.16 | $-7.57M ▲ |
| Q2-2025 | $17K ▼ | $9.3M ▲ | $-8.05M ▲ | -47.33K% ▼ | $-0.16 ▲ | $-7.81M ▲ |
| Q1-2025 | $38K ▲ | $9.25M ▼ | $-8.19M ▲ | -21.54K% ▲ | $-0.2 ▲ | $-7.97M ▲ |
| Q4-2024 | $24K ▼ | $9.41M ▲ | $-8.58M ▼ | -35.75K% ▼ | $-0.25 ▼ | $-8.36M ▼ |
| Q3-2024 | $29K | $8.88M | $-7.92M | -27.31K% | $-0.24 | $-7.71M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $43.3M ▲ | $108.13M ▼ | $25.94M ▲ | $82.18M ▼ |
| Q2-2025 | $40.16M ▼ | $111.83M ▼ | $23.6M ▲ | $88.23M ▼ |
| Q1-2025 | $46.2M ▼ | $118.18M ▲ | $23.4M ▼ | $94.78M ▲ |
| Q4-2024 | $46.24M ▼ | $72.58M ▼ | $24.77M ▲ | $47.8M ▼ |
| Q3-2024 | $49.75M | $79M | $24.35M | $54.65M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-7.81M ▲ | $-6.48M ▼ | $5.17M ▼ | $373K ▲ | $-935K ▼ | $-6.59M ▼ |
| Q2-2025 | $-8.05M ▲ | $-5.47M ▲ | $5.24M ▲ | $18K ▼ | $-214K ▼ | $-5.75M ▲ |
| Q1-2025 | $-8.19M ▲ | $-7.55M ▼ | $-44.8M ▼ | $53.54M ▲ | $1.19M ▼ | $-7.56M ▼ |
| Q4-2024 | $-8.58M ▼ | $-6.26M ▲ | $7.38M ▲ | $234K ▲ | $1.36M ▲ | $-6.32M ▲ |
| Q3-2024 | $-7.92M | $-7M | $4.9M | $117K | $-1.98M | $-7.32M |
CEO
Evguenia Lindgardt
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 13
Ratings Snapshot
Rating : C
Price Target
Institutional Ownership
BAKER BROS. ADVISORS LP
Shares:5.5M
Value:$19.46M
WHETSTONE CAPITAL ADVISORS, LLC
Shares:3.63M
Value:$12.86M
INTERWEST VENTURE MANAGEMENT CO
Shares:2.42M
Value:$8.55M
Summary
Showing Top 3 of 70